Ricafrente, Roel Jr .
HRN: 26-33-29 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/04/2024
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
12/04/2024
12/11/2024
IV
150mg
Q24hrs
Pcap C
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes